B+
Bull case
25%
Probability
Target price
$23.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
SGRY
Surgery PartnersANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$18.70
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$10.50
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-09
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+93.2
Score
AI commentary
Tone is mixed but improved from the prior monitoring baseline: Q2 guidance was reaffirmed and operating execution showed same-facility revenue growth, while EBITDA and case growth remained soft. Two director open-market purchases on August 18 provide a modest supportive signal but are not evidence of operating improvement. [#SEC-FORM4-2026-08-19] [#SEC-FORM4-2026-08-20] Social sentiment, options skew, short interest and confirmed post-print price reaction are unavailable, so conviction remains moderate.
RankAlpha Sentiment Codex - 2026-09-09
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-08eventIdaho Falls transaction closingHigh impact
The pending Idaho Falls divestiture could improve cash conversion and support deleveraging, but remains subject to physician-member and governing-board approvals. [#SEC-8K-2026-08-10]
2026-12-08catalystHigher-acuity growth converts into EBITDA stabilizationHigh impact
Q2 same-facility revenue rose 5.0% and revenue per case rose 4.8%, but same-facility cases increased only 0.3% and Adjusted EBITDA declined to $125.2 million from $129.0 million. Second-half margin stabilization against reaffirmed 2026 guidance is the key near-term test. [#SEC-8K-2026-08-10]
2027-09-09catalystASC platform and higher-acuity procedure runwayHigh impact
Management continues to cite structural ASC market growth, higher-acuity procedures, operational efficiency and disciplined capital allocation as long-term value drivers. The modest case growth in Q2 means sustained execution and cash-flow conversion remain necessary. [#SEC-8K-2026-08-10]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-09 • Updated nightlySource: Internal modelMethodology